INmune Bio (NASDAQ:INMB) Downgraded by Wall Street Zen to “Sell”

INmune Bio (NASDAQ:INMB) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INmune Bio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $18.00.

INmune Bio Price Performance

Shares of NASDAQ INMB opened at $1.91 on Friday. INmune Bio has a 1 year low of $1.38 and a 1 year high of $11.64. The stock has a market capitalization of $50.77 million, a P/E ratio of -0.90 and a beta of 0.91. The company’s 50-day moving average is $1.76 and its 200 day moving average is $3.11.

INmune Bio (NASDAQ:INMB) last issued its quarterly earnings data on Thursday, October 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.07. Research analysts anticipate that INmune Bio will post -2.24 earnings per share for the current year.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently made changes to their positions in INMB. Intech Investment Management LLC purchased a new position in shares of INmune Bio during the second quarter valued at approximately $26,000. PFG Investments LLC purchased a new stake in shares of INmune Bio in the 2nd quarter worth approximately $27,000. Cary Street Partners Financial LLC bought a new position in INmune Bio during the 3rd quarter valued at approximately $29,000. Independent Advisor Alliance bought a new position in INmune Bio during the 3rd quarter valued at approximately $30,000. Finally, Squarepoint Ops LLC purchased a new position in INmune Bio during the third quarter valued at $30,000. Institutional investors own 12.72% of the company’s stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.